CV Sciences (CVSI)
(Delayed Data from OTC)
$0.06 USD
-0.02 (-22.85%)
Updated Jun 17, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
CV Sciences, Inc. [CVSI]
Reports for Purchase
Showing records 21 - 40 ( 67 total )
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Q/Q Growth, Regulatory Uncertainty Remains, Lower PT to $0.50
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Preview; Product Innovation Key to Expansion
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Week II Earnings Preview: Expect U.S. MSO and Ancillary Strength
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Muted Results, Expecting Incremental Growth on New Product Launches
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Earnings Week I Preview: 1Q Muted By COVID/Seasonality, 2H21 Acceleration
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Cannabis State of the Union: Legislative Tailwinds & Positioned for 2H Strength
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
The Weekly Rehash: NY and NM Legalize Cannabis and Another Round of M&A
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
INVITE: Roth Virtual Golden Cannabis Day - April 7, 2021
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Results Same Weakness Limited Visibility, Remain Neutral PT to $0.60
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Cannabis Industry 3Q & Election Recap: Bifurcation in Markets and Returns
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Cannabis Industry Policy: Historic Policy Movement Globally
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Reports 3Q20 Modest Sequential Growth, Product Roll-Outs On Deck
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Preview, New Initiatives Traction to Improve Outlook
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S